The vaccine industry in the United States finds itself at a critical juncture, where an unprecedented level of bipartisan support offers a glimmer of hope amid swirling controversies, technological debates, and regulatory uncertainties that could shape its future trajectory. A recent poll conducted
In a landscape where millions of patients with advanced chronic kidney disease (CKD) struggle with limited and often burdensome treatment options, a groundbreaking development has emerged to potentially transform their lives. Opterion Health AG, a clinical-stage biopharmaceutical company
What if a single policy change could jeopardize decades of progress in safeguarding children from a silent, deadly virus, and what would be the consequences of such a shift? The debate over delaying the hepatitis B vaccine from birth to age 4 has erupted into a heated controversy, pitting public
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technology and innovation in the industry. Today, we’re diving into a pressing topic: the potential connection between processed red
In an era where access to reliable health information can make a significant difference in public safety, South Korea's Ministry of Food and Drug Safety is taking bold steps to enhance its digital resources for medical devices. With millions of people relying on accurate data to make informed
Brazil is emerging as a formidable force in the global clinical research arena, thanks to the recent enactment of Law 14.784/14, a pivotal regulation designed to overhaul the nation’s approach to clinical trials. Spearheaded by ANVISA, Brazil’s health regulatory agency, this legislation targets
